Professor | Zuojiong Gong | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Zuojiong Gong
Contact Information	zjgong@163.com
Language ability	English, Chinese
Province	Hubei

Upload Avatar (500 x 500)

Name

Zuojiong Gong

Contact Information

zjgong@163.com

Language ability

English, Chinese

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Medical School
Academic Background & Achievements	1984.09-1987.07 Master's in Infectious Diseases, Wuhan University 1993.10-1998.05 PhD in Medicine, Catholic University of Leuven, Belgium Postdoctoral Researcher at Catholic University of Leuven, Belgium (1998.05-1998.12)
Work Experience	1988.05-1991.09 Attending Physician, Department of Infectious Diseases, Renmin Hospital of Wuhan University 1991.10-1993.09 Associate Professor, Department of Infectious Diseases, Renmin Hospital of Wuhan University 1999.01-1999.12 Professor, Department of Infectious Diseases, Renmin Hospital of Wuhan University 2000.01-present Doctoral Supervisor, Department of Infectious Diseases, Renmin Hospital of Wuhan University
Awards	2002 Third Prize, Hubei Province Natural Science Award: Research on Hepatitis B Virus Receptors 2003 Third Prize, Hubei Province Natural Science Award: Establishment of an In Vitro Hepatitis B Virus Infection Model and Evaluation of Antiviral Drugs 2006 Third Prize, Hubei Province Science and Technology Progress Award: Experimental and Clinical Study on Anti-Liver Fibrosis of Chinese Medicine Jin San E 2011 Third Prize, Hubei Province Science and Technology Progress Award: Molecular Epidemiology of HIV-1 in Hubei Region 2014 Third Prize, Hubei Province Science and Technology Progress Award: Basic and Clinical Study on Methyl Donors (S-Adenosylmethionine and Betaine) in the Treatment of Chronic Liver Diseases 2015 Third Prize, Hubei Province Science and Technology Progress Award: Experimental and Clinical Study on Anti-Liver Fibrosis Treatment 2022 Second Prize, Hubei Province Science and Technology Progress Award: Key Diagnostic and Therapeutic Techniques Innovation and Clinical Application in Liver Failure

University/Lab Affiliation and Title

Wuhan University

Faculty

Medical School

Academic Background & Achievements

1984.09-1987.07 Master's in Infectious Diseases, Wuhan University
1993.10-1998.05 PhD in Medicine, Catholic University of Leuven, Belgium
Postdoctoral Researcher at Catholic University of Leuven, Belgium (1998.05-1998.12)

Work Experience

1988.05-1991.09 Attending Physician, Department of Infectious Diseases, Renmin Hospital of Wuhan University
1991.10-1993.09 Associate Professor, Department of Infectious Diseases, Renmin Hospital of Wuhan University
1999.01-1999.12 Professor, Department of Infectious Diseases, Renmin Hospital of Wuhan University
2000.01-present Doctoral Supervisor, Department of Infectious Diseases, Renmin Hospital of Wuhan University

Awards

2002 Third Prize, Hubei Province Natural Science Award: Research on Hepatitis B Virus Receptors
2003 Third Prize, Hubei Province Natural Science Award: Establishment of an In Vitro Hepatitis B Virus Infection Model and Evaluation of Antiviral Drugs
2006 Third Prize, Hubei Province Science and Technology Progress Award: Experimental and Clinical Study on Anti-Liver Fibrosis of Chinese Medicine Jin San E
2011 Third Prize, Hubei Province Science and Technology Progress Award: Molecular Epidemiology of HIV-1 in Hubei Region
2014 Third Prize, Hubei Province Science and Technology Progress Award: Basic and Clinical Study on Methyl Donors (S-Adenosylmethionine and Betaine) in the Treatment of Chronic Liver Diseases
2015 Third Prize, Hubei Province Science and Technology Progress Award: Experimental and Clinical Study on Anti-Liver Fibrosis Treatment
2022 Second Prize, Hubei Province Science and Technology Progress Award: Key Diagnostic and Therapeutic Techniques Innovation and Clinical Application in Liver Failure

Areas of Focus	Chronic liver disease: Mechanism of chronicity in HBV infection, inflammatory mechanisms in liver failure, clinical rescue treatments. Viral diseases: Immunological mechanisms of viral infections, gene therapy strategies to inhibit viral replication.
Publications	Pinocembrin ameliorates acute liver failure via activating the Sirt1/PPARα pathway in vitro and in vivo, Cao P, Chen Q, Shi C, Pei M, Wang L, Gong Z, 2022 Sirtuin1 attenuates acute liver failure by reducing reactive oxygen species via hypoxia inducible factor 1α, Cao P, Chen Q, Shi CX, Wang LW, Gong ZJ, 2022 Fusobacterium nucleatum promotes the development of acute liver failure by inhibiting the NAD+ salvage metabolic pathway, Cao P, Chen Q, Shi C, Wang L, Gong Z, 2022 Changes of flavin-containing monooxygenases and trimethylamine- N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine, Shi C, Pei M, Wang Y, Chen Q, Cao P, Zhang L, Guo J, Deng W, Wang L, Li X, Gong Z, 2022 SIRT3 inhibitor 3-TYP exacerbates thioacetamide-induced hepatic injury in mice, Shi C, Jiao F, Wang Y, Chen Q, Wang L, Gong Z, 2022 NOD2-mediated HDAC6/NF-κb signalling pathway regulates ferroptosis induced by extracellular histone H3 in acute liver failure, Chen Q, Zhang Q, Cao P, Shi C, Zhang L, Wang L, Gong Z, 2022 Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective, Guo J, Shi CX, Zhang QQ, Deng W, Zhang LY, Chen Q, Zhang DM, Gong ZJ, 2022 Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD, Li X, Hong J, Wang Y, Pei M, Wang L, Gong Z, 2021 Role of SIRT1 in Hepatic Encephalopathy: In Vivo and In Vitro Studies Focusing on the NLRP3 Inflammasome, Jiao F, Wang Y, Chen Q, Cao P, Shi C, Pei M, Wang L, Gong Z, 2021 Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure, Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2021 The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients, Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2021 Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site, Wang Y, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2021 HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway, Chen Q, Wang Y, Jiao F, Cao P, Shi C, Pei M, Wang L, Gong Z, 2021 Epigenetic Regulation of Hepatic Stellate Cell Activation and Macrophage in Chronic Liver Inflammation, Shi CX, Wang Y, Jiao FZ, Chen Q, Cao P, Pei MH, Zhang LY, Guo J, Deng W, Wang LW, Gong ZJ, 2021 TNF-α/HMGB1 inflammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury, Wang Y, Zhang HY, Chen Q, Jiao FZ, Shi CX, Pei MH, Lv J, Zhang H, Wang LW, Gong ZJ, 2020 Clinical Challenges in an Outbreak of COVID-19 in Wuhan, China: Concerns from Frontiers, Wang Y, Wang L, Li X, Gong Z, 2020 Histone Deacetylase 6 Inhibitor ACY1215 Ameliorates Mitochondrial Dynamic and Function Injury in Hepatocytes by Activating AMPK Signaling Pathway in Acute Liver Failure Mice, Chen Q, Wang Y, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2020 Betaine inhibits Toll-like receptor 4 responses and restores intestinal microbiota in acute liver failure mice, Chen Q, Wang Y, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2020 Extracellular Histone H3 Induces Pyroptosis During Sepsis and May Act Through NOD2 and VSIG4/NLRP3 Pathways, Shi CX, Wang Y, Chen Q, Jiao FZ, Pei MH, Gong ZJ Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China

Areas of Focus

Chronic liver disease: Mechanism of chronicity in HBV infection, inflammatory mechanisms in liver failure, clinical rescue treatments.
Viral diseases: Immunological mechanisms of viral infections, gene therapy strategies to inhibit viral replication.

Publications

Pinocembrin ameliorates acute liver failure via activating the Sirt1/PPARα pathway in vitro and in vivo, Cao P, Chen Q, Shi C, Pei M, Wang L, Gong Z, 2022
Sirtuin1 attenuates acute liver failure by reducing reactive oxygen species via hypoxia inducible factor 1α, Cao P, Chen Q, Shi CX, Wang LW, Gong ZJ, 2022
Fusobacterium nucleatum promotes the development of acute liver failure by inhibiting the NAD+ salvage metabolic pathway, Cao P, Chen Q, Shi C, Wang L, Gong Z, 2022
Changes of flavin-containing monooxygenases and trimethylamine- N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine, Shi C, Pei M, Wang Y, Chen Q, Cao P, Zhang L, Guo J, Deng W, Wang L, Li X, Gong Z, 2022
SIRT3 inhibitor 3-TYP exacerbates thioacetamide-induced hepatic injury in mice, Shi C, Jiao F, Wang Y, Chen Q, Wang L, Gong Z, 2022
NOD2-mediated HDAC6/NF-κb signalling pathway regulates ferroptosis induced by extracellular histone H3 in acute liver failure, Chen Q, Zhang Q, Cao P, Shi C, Zhang L, Wang L, Gong Z, 2022
Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective, Guo J, Shi CX, Zhang QQ, Deng W, Zhang LY, Chen Q, Zhang DM, Gong ZJ, 2022
Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD, Li X, Hong J, Wang Y, Pei M, Wang L, Gong Z, 2021
Role of SIRT1 in Hepatic Encephalopathy: In Vivo and In Vitro Studies Focusing on the NLRP3 Inflammasome, Jiao F, Wang Y, Chen Q, Cao P, Shi C, Pei M, Wang L, Gong Z, 2021
Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure, Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2021
The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients, Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2021
Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site, Wang Y, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2021
HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway, Chen Q, Wang Y, Jiao F, Cao P, Shi C, Pei M, Wang L, Gong Z, 2021
Epigenetic Regulation of Hepatic Stellate Cell Activation and Macrophage in Chronic Liver Inflammation, Shi CX, Wang Y, Jiao FZ, Chen Q, Cao P, Pei MH, Zhang LY, Guo J, Deng W, Wang LW, Gong ZJ, 2021
TNF-α/HMGB1 inflammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury, Wang Y, Zhang HY, Chen Q, Jiao FZ, Shi CX, Pei MH, Lv J, Zhang H, Wang LW, Gong ZJ, 2020
Clinical Challenges in an Outbreak of COVID-19 in Wuhan, China: Concerns from Frontiers, Wang Y, Wang L, Li X, Gong Z, 2020
Histone Deacetylase 6 Inhibitor ACY1215 Ameliorates Mitochondrial Dynamic and Function Injury in Hepatocytes by Activating AMPK Signaling Pathway in Acute Liver Failure Mice, Chen Q, Wang Y, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2020
Betaine inhibits Toll-like receptor 4 responses and restores intestinal microbiota in acute liver failure mice, Chen Q, Wang Y, Jiao F, Shi C, Pei M, Wang L, Gong Z, 2020
Extracellular Histone H3 Induces Pyroptosis During Sepsis and May Act Through NOD2 and VSIG4/NLRP3 Pathways, Shi CX, Wang Y, Chen Q, Jiao FZ, Pei MH, Gong ZJ
Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China

Hbv Chronicity Inflammation Liver Failure Clinical Treatments Viral Infections Immunology Gene Therapy Virus Replication Clinical Research

Huan Liu - Wuhan University

Weiguo Dong - Wuhan University

Hanxiang Nie - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us